Resmed Q1 revenue rises 6% to $1.4B; EPS up 14% non-GAAP, returns $1B to shareholders

Resmed reported a 6% revenue increase to $1.4 billion in Q1 fiscal 2027, driven by strong demand for sleep and breathing health products. Non-GAAP diluted earnings per share rose 14% to $2.91, supported by improved gross margins and operational efficiency. The company returned over $1 billion to shareholders through dividends and share buybacks, while investing in innovation and expanding its digital health ecosystem. Resmed expects to continue growing its core business and enhancing home-based care solutions throughout the fiscal year.

As of Oct 30, 2026 03:12 WIB, ResMed Inc. (RMD) shares are trading at USD 258.40 on Pluang, showing a 3.29% increase in the last day. The company holds a market capitalization of $35.18 billion and offers a dividend yield of 1.06%. This performance highlights investor interest alongside the company's ongoing growth and shareholder returns.